Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors

被引:42
作者
Bitan, M.
Or, R.
Shapira, M. Y.
Aker, M.
Resnick, I. B.
Ackerstein, A.
Samuel, S.
Elad, S.
Slavin, S. [1 ]
机构
[1] Hadassah Univ Hosp, Dept Bone Marrow Transplantat & Canc Immunotherap, IL-91120 Jerusalem, Israel
[2] Hadassah Univ Hosp, Dept Pediat, Pediat Hematol Oncol Unit, IL-91120 Jerusalem, Israel
关键词
Fanconi anemia; reduced intensity conditioning; stem cell transplantation; fludarabine;
D O I
10.1016/j.bbmt.2006.03.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Reduced intensity conditioning has been suggested as a desirable therapeutic modality for the treatment of patients with malignant and :nonmalignant indications, but it seems particularly attractive for patients with Fanconi anemia due to their increased sensitivity to chemoradiotherapy. Between November 1996 and September 2003, 7 patients (1 male and 6 female; age range, 3-31 years; median age, 9.5) were conditioned with a fludarabine-based protocol for stem cell transplantation without radiation. In vivo T-cell depletion was accomplished with anti-thymocytic globulin or Campath-1H (alemtuzumab). Graft-versus-host disease prophylaxis consisted of low-dose cyclosporine alone. Eight transplantations were carried out for 7 patients using bone marrow, peripheral blood, and/or cord blood as sources of stem cells. All patients received transplants from HLA-A, -B, -C, and -DR. matched donors, 5 from family members and 2 from matched unrelated donors. One patient did not engraft her first matched unrelated donor and underwent a second transplantation from another matched unrelated donor, after which she engrafted well. All 7 patients are alive and well, fully reconstituted with donor cells, and with 100% performance status. In conclusion, fludarabine-based preparative protocols are well tolerated, facilitate rapid engraftment with minimal toxicity, and should be considered an essential component of choice for patients with Fanconi anemia. (C) 2006 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:712 / 718
页数:7
相关论文
共 30 条
[1]   Fludarabine-based protocol for human umbilical cord blood transplantation in children with fanconi anemia [J].
Aker, M ;
Varadi, G ;
Slavin, S ;
Nagler, A .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1999, 21 (03) :237-239
[2]  
AUERBACH AD, 2002, GENETIC BASIS HUMAN, P317
[3]  
BERGER R, 1980, BRIT J HAEMATOL, V45, P565, DOI 10.1111/j.1365-2141.1980.tb07179.x
[4]   Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts [J].
Boulad, F ;
Gillio, A ;
Small, TN ;
George, D ;
Prasad, V ;
Torok-Castanza, J ;
Regan, AD ;
Collins, N ;
Auerbach, AD ;
Kernan, NA ;
O'Reilly, RJ .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (04) :1153-1157
[5]   Low risk of graft-versus-host disease with transplantation of CD34 selected peripheral blood progenitor cells from alternative donors for Fanconi anemia [J].
Boyer, MW ;
Gross, TG ;
Loechelt, B ;
Leemhuis, T ;
Filipovich, A ;
Harris, RE .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2003, 25 (11) :890-895
[6]  
Champlin R, 1999, ONCOLOGY-NY, V13, P621
[7]   Unrelated cord blood transplantion in a Fanconi anemia patient using fludarabine-based conditioning [J].
de Medeiros, CR ;
Silva, LM ;
Pasquini, R .
BONE MARROW TRANSPLANTATION, 2001, 28 (01) :110-112
[8]   Stem cell transplantation from HLA-matched related donor for Fanconi's anaemia: a retrospective review of the multicentric Italian experience on behalf of Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP)-Gruppo Italiano Trapianto di Midollo Osseo (GITMO) [J].
Dufour, C ;
Rondelli, R ;
Locatelli, F ;
Miano, M ;
Di Girolamo, G ;
Bacigalupo, A ;
Messina, C ;
Porta, F ;
Balduzzi, A ;
Iorio, AP ;
Buket, E ;
Madon, E ;
Pession, A ;
Dini, G ;
Di Bartolomeo, P .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (03) :796-805
[9]  
Giampietro PF, 1997, AM J MED GENET, V68, P58, DOI 10.1002/(SICI)1096-8628(19970110)68:1<58::AID-AJMG11>3.3.CO
[10]  
2-K